Australia markets open in 36 minutes

Regeneron Pharmaceuticals, Inc. (REGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
622.15-8.48 (-1.34%)
At close: 04:00PM EDT
622.50 +0.35 (+0.06%)
After hours: 05:15PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 66.87B
Enterprise value 62.52B
Trailing P/E 8.64
Forward P/E 14.04
PEG ratio (5-yr expected) 5.30
Price/sales (ttm)4.16
Price/book (mrq)3.36
Enterprise value/revenue 4.39
Enterprise value/EBITDA 9.34

Trading information

Stock price history

Beta (5Y monthly) 0.28
52-week change 32.54%
S&P500 52-week change 3-6.69%
52-week high 3747.42
52-week low 3538.01
50-day moving average 3601.23
200-day moving average 3633.45

Share statistics

Avg vol (3-month) 3668.23k
Avg vol (10-day) 3659.93k
Shares outstanding 5107.19M
Implied shares outstanding 6N/A
Float 8102.29M
% held by insiders 12.71%
% held by institutions 188.16%
Shares short (14 July 2022) 42.86M
Short ratio (14 July 2022) 44.42
Short % of float (14 July 2022) 42.76%
Short % of shares outstanding (14 July 2022) 42.60%
Shares short (prior month 14 June 2022) 42.58M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 June 2022

Profitability

Profit margin 39.97%
Operating margin (ttm)49.77%

Management effectiveness

Return on assets (ttm)18.18%
Return on equity (ttm)31.76%

Income statement

Revenue (ttm)14.23B
Revenue per share (ttm)133.27
Quarterly revenue growth (yoy)-44.40%
Gross profit (ttm)10.73B
EBITDA 7.38B
Net income avi to common (ttm)5.69B
Diluted EPS (ttm)49.86
Quarterly earnings growth (yoy)-72.50%

Balance sheet

Total cash (mrq)7.57B
Total cash per share (mrq)70.78
Total debt (mrq)2.7B
Total debt/equity (mrq)13.06
Current ratio (mrq)5.12
Book value per share (mrq)192.62

Cash flow statement

Operating cash flow (ttm)8.45B
Levered free cash flow (ttm)6.24B